tradeherpete
3 minutes ago
Blarcamesine will be approved by the EMA.
The barrier that Lec, Adu, Doncorleonamab faced isn't the incremental reduction in decline, its the awful adverse side effects. Brain bleeding ARIA, swelling, death. Those are big turn offs.
Had approval been sought before the